British Patient Capital
British Patient Capital is a subsidiary of the British Business Bank, established in 2018 to support UK companies requiring long-term, patient investment. It commits capital to venture and venture growth funds that back innovative businesses across the country, with a particular emphasis on scaling high-potential companies. Operating primarily as a fund-of-funds and co-investor, it has made commitments to funds managed by firms including Balderton Capital, Amadeus Capital Partners, and IQ Capital, helping bridge the funding gap for UK technology and life sciences companies.
Focus Areas
Portfolio
2 companies in our directory
Paragraf
Paragraf is a University of Cambridge spinout founded in 2017 by Simon Thomas (CEO), Professor Sir Colin Humphreys, and Ivor Guiney. The company commercialises graphene and other two-dimensional materials at scale using standard semiconductor fabrication equipment, with a proprietary direct deposition technique that produces device-quality graphene on 8-inch wafers without metal catalysts or transfer processes. Paragraf launched its first product in 2019, a graphene-based Hall-effect sensor offering 30x greater sensitivity than conventional silicon at one-tenth the power. The sensor portfolio has expanded to include molecular sensors for healthcare, agritech, food production, and chemical manufacturing. The company has raised over £140M across four rounds, including a $55M Series C in 2025 led by Mubadala.
Cambridge GaN Devices
HiringCambridge GaN Devices was spun out from Cambridge University's Department of Engineering in 2016 by Dr Giorgia Longobardi (CEO) and Professor Florin Udrea (CTO). The fabless semiconductor company designs and commercialises gallium nitride power transistors and integrated circuits through its proprietary ICeGaN technology, enabling energy efficiency levels exceeding 99% and reducing energy consumption by up to 50% in applications including data centre power supplies and automotive electric vehicles. The technology builds on decades of GaN research at Cambridge, with Udrea's work recognised through induction into the ISPSD Hall of Fame. The company raised $32M in a Series C in February 2025, bringing total funding to over $60M from investors including IQ Capital, ParkWalk, BGF, Cambridge Innovation Capital, Foresight Group, and British Patient Capital.